The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

PE-22-28

Research chemical · Grade C

Goals
cognition, sleep
Evidence
—
Routes
injectable-sc, nasal
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
The limitation: spadin's half-life in vivo was approximately 7 hours, limiting its duration of action.
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Adamax

Research chemical · Grade C

Goals
cognition
Evidence
0 RCT / 2 animal / 0 in vitro
Routes
injectable-sc, nasal
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

N-Acetyl Semax Amidate

Research chemical · Grade C

Goals
cognition
Evidence
0 RCT / 0 animal / 0 in vitro
Routes
injectable-sc, nasal
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
The resulting compound has an estimated half-life of 4-6 hours — a massive pharmacokinetic advantage over Semax's 3-5 minutes — without altering the core sequence that interacts…
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

DSIP

Research chemical · Grade C

Goals
cognition, sleep
Evidence
1 RCT / 6 animal / 1 in vitro
Routes
injectable-sc, nasal
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
In animal studies: the half-life appears even shorter — approximately 4-5 minutes in vivo
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →